Department of Neurology, University Hospital "12 de Octubre", Madrid, Spain.
Neural and Cognitive Engineering Group, Center for Automation and Robotics, CSIC-UPM, Arganda del Rey, Spain.
J Med Internet Res. 2021 May 27;23(5):e25988. doi: 10.2196/25988.
Early detection and intervention are the key factors for improving outcomes in patients with COVID-19.
The objective of this observational longitudinal study was to identify nonoverlapping severity subgroups (ie, clusters) among patients with COVID-19, based exclusively on clinical data and standard laboratory tests obtained during patient assessment in the emergency department.
We applied unsupervised machine learning to a data set of 853 patients with COVID-19 from the HM group of hospitals (HM Hospitales) in Madrid, Spain. Age and sex were not considered while building the clusters, as these variables could introduce biases in machine learning algorithms and raise ethical implications or enable discrimination in triage protocols.
From 850 clinical and laboratory variables, four tests-the serum levels of aspartate transaminase (AST), lactate dehydrogenase (LDH), C-reactive protein (CRP), and the number of neutrophils-were enough to segregate the entire patient pool into three separate clusters. Further, the percentage of monocytes and lymphocytes and the levels of alanine transaminase (ALT) distinguished cluster 3 patients from the other two clusters. The highest proportion of deceased patients; the highest levels of AST, ALT, LDH, and CRP; the highest number of neutrophils; and the lowest percentages of monocytes and lymphocytes characterized cluster 1. Cluster 2 included a lower proportion of deceased patients and intermediate levels of the previous laboratory tests. The lowest proportion of deceased patients; the lowest levels of AST, ALT, LDH, and CRP; the lowest number of neutrophils; and the highest percentages of monocytes and lymphocytes characterized cluster 3.
A few standard laboratory tests, deemed available in all emergency departments, have shown good discriminative power for the characterization of severity subgroups among patients with COVID-19.
早期检测和干预是改善 COVID-19 患者预后的关键因素。
本观察性纵向研究的目的是根据在急诊科评估患者时获得的临床数据和标准实验室检查结果,确定 COVID-19 患者之间无重叠的严重程度亚组(即聚类)。
我们应用无监督机器学习方法对来自西班牙马德里 HM 医院集团(HM Hospitales)的 853 例 COVID-19 患者的数据进行了分析。在构建聚类时不考虑年龄和性别,因为这些变量可能会使机器学习算法产生偏差,并引发伦理问题或导致分诊协议中的歧视。
从 850 个临床和实验室变量中,有四项测试——血清天门冬氨酸转氨酶(AST)、乳酸脱氢酶(LDH)、C 反应蛋白(CRP)和中性粒细胞计数——足以将整个患者群体分为三个独立的聚类。此外,单核细胞和淋巴细胞的百分比以及丙氨酸转氨酶(ALT)水平可将第 3 个聚类的患者与其他两个聚类区分开来。第 1 个聚类的患者死亡率最高,AST、ALT、LDH 和 CRP 水平最高,中性粒细胞计数最高,单核细胞和淋巴细胞的百分比最低。第 2 个聚类的患者死亡率较低,上述实验室检测的水平也较低。第 3 个聚类的患者死亡率最低,AST、ALT、LDH 和 CRP 水平最低,中性粒细胞计数最低,单核细胞和淋巴细胞的百分比最高。
一些标准实验室测试,被认为在所有急诊科都可用,对 COVID-19 患者严重程度亚组的特征具有良好的区分能力。